Although the number of relevant studies included in the separate analysis was not sufficiently large, valuable evidence was nevertheless provided by synthesizing all of the published data, proving that the CC vs. CA model of the VEGF -2578 C/A polymorphism and the CC+CT vs. TT model of the VEGF -460 C/T polymorphism might be predictive factors to responsiveness to chemotherapy in CRC. The gene discussed is VEGFA; the disease is colorectal carcinoma.